These studies highlight the opportunity provided by organoid models with Cntnap2 edition for the development of new therapeutic strategies for ASD.[191] Furthermore, brain organoids derived from iPSCs of healthy controls and patients with primary progressive multiple sclerosis (PPMS), secondary progressive MS (SPMS), and relapsing‐remitting MS (RRMS) revealed an association between stem cell dysregulation in the stem cell pool and reduced expression of the cell cycle inhibitor p21. Here, CNTNAP2 is linked to secondary progressive multiple sclerosis.